Sobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune Thrombocytopenia
December 12, 2024 06:59 ET
|
Sobi, Inc.
WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration...
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
July 02, 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia
November 06, 2023 13:07 ET
|
Sobi, Inc.
Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia